Literature DB >> 15075622

Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm.

J De Vry1, K R Jentzsch.   

Abstract

Both cannabinoid CB1 receptor agonists, such as delta-tetrahydrocannabinol (delta-THC), CP 55,940 and WIN 55,212-2, and the antagonist/inverse agonist SR141716A, dose-dependently suppress operant behavior. The present study investigated to what extent combined i.p. application of SR141716A with these cannabinoids resulted in mutually antagonistic effects, in additive effects, or in no interactive effects on operant responding in rats trained in a fixed-ratio 10, food-reinforced 10-min procedure. Pretreatment with SR141716A either had no effect on (at 0.3-1mg/kg), or partially blocked (at 3 mg/kg), the inhibitory effects on responding induced by delta-THC (3-5 mg/kg) and CP 55,940 (0.03-0.2 mg/kg). Interestingly, while 3 mg/kg SR141716A induced moderate inhibitory effects on operant responding, its combination with either agonist resulted in the same level of inhibitory activity on responding as that obtained by SR141716A when tested alone. Pretreatment with a low dose of CP 55,940 (0.01 mg/kg) or WIN 55,212-2 (0.3 mg/kg) did not affect response inhibition induced by SR141716A. Combination of SR141716A (0.5 and 1mg/kg) with delta-THC (3 mg/kg) resulted in the same level of response inhibition, independently of whether SR141716A was given 5 min before or 15 min after delta-THC. Although alternative explanations are conceivable, the data may indicate that SR141716A is a partial agonist at those cannabinoid receptors mediating the response-rate suppressive effects of cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075622     DOI: 10.1097/00008877-200402000-00002

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  12 in total

1.  Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.

Authors:  Lance R McMahon
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

2.  Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure.

Authors:  Julie A Marusich; Jenny L Wiley
Journal:  Pharmacol Biochem Behav       Date:  2012-03-09       Impact factor: 3.533

3.  Microstructural analysis of rat ethanol and water drinking patterns using a modified operant self-administration model.

Authors:  Stacey L Robinson; Brian A McCool
Journal:  Physiol Behav       Date:  2015-05-31

4.  Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.

Authors:  Vanessa Minervini; Sujata Dahal; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2016-11-30       Impact factor: 4.030

5.  CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat.

Authors:  Styliani Vlachou; George G Nomikos; George Panagis
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

6.  Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.

Authors:  Torbjörn U C Järbe; Roger S Gifford; Alexandros Makriyannis
Journal:  Eur J Pharmacol       Date:  2010-09-18       Impact factor: 4.432

7.  Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054.

Authors:  Peter J McLaughlin; Ganesh A Thakur; V Kiran Vemuri; Evan D McClure; Cara M Brown; Keisha M Winston; Jodianne T Wood; Alexandros Makriyannis; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2013-04-19       Impact factor: 3.533

8.  Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.

Authors:  Lance R McMahon; Wouter Koek
Journal:  Eur J Pharmacol       Date:  2007-05-22       Impact factor: 4.432

9.  Blockade of CB1 receptors prevents retention of extinction but does not increase low preincubated conditioned fear in the fear incubation procedure.

Authors:  Charles L Pickens; Florence R Theberge
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

10.  Modulation of excitatory synaptic transmission by Delta 9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate.

Authors:  Alan M Roloff; Stanley A Thayer
Journal:  Mol Pharmacol       Date:  2008-12-31       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.